BiotechTube
TRIMT

TRIMT

Berlin, Germany· Est.
trimt.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

TRIMT is a private, inventor-founded biotech company pioneering targeted radiopharmaceuticals for cancer theranostics. Its pipeline is centered on novel compounds targeting integrins like αvβ6 and αvβ8, as well as PD-L1, for both diagnostic imaging and radioligand therapy. The company leverages a strong scientific foundation, key academic collaborations, and an experienced leadership team to translate its discoveries from preclinical development into clinical trials.

Oncology

Technology Platform

TRAP (Tehraheran Assay Platform) technology for developing chelator-conjugated peptide-based radiopharmaceuticals, enabling matched diagnostic and therapeutic pairs (theranostics) targeting specific biomarkers like integrins.

Funding History

2
Total raised:$4M
Seed$3.2M
Grant$800K

Opportunities

The booming radiopharmaceutical theranostics market, driven by successful products like Pluvicto, presents a massive commercial opportunity.
TRIMT's focus on novel, high-potential targets like αvβ6 integrin and PD-L1 positions it to address large, underserved patient populations with aggressive solid tumors.
Strong academic and clinical networks in Europe provide a favorable ecosystem for translational development.

Risk Factors

The company faces high clinical development risk as its novel compounds must prove safe and effective in humans.
Securing sufficient funding to advance through costly clinical trials is a critical challenge.
Intensifying competition in the radiopharmaceutical space from larger, well-resourced companies threatens market positioning.

Competitive Landscape

TRIMT competes in the rapidly evolving targeted radiopharmaceutical space against large-cap players (e.g., Novartis, Bayer) and a growing number of biotechs. Its differentiation lies in its focus on novel integrin targets (αvβ6, αvβ8) and a proprietary platform. Competition is fierce for talent, funding, and clinical validation, but first-mover advantage in its specific target niches could be significant.

More companies in Diagnostics & Precision Medicine →More companies in Germany →